Genetic Risk for Heart Disease: DNA Variants That Affect Cardiovascular Health
Genetics account for 40–60% of heart disease risk. PCSK9, LDLR, and the 9p21 locus are key. Learn what DNA reveals about coronary artery disease, FH, and atrial fibrillation.
Category: Diagnostics · By GenomeNarrator Team · · 7 min read
Coronary artery disease (CAD) is one of the most heritable common conditions: studies suggest genetics account for roughly 40–60% of the variance in risk. Yet the genetic architecture is complex, involving hundreds of variants each with small individual effects.
The LDL cholesterol genes
Variants in PCSK9, LDLR, and APOB directly affect how your body clears LDL cholesterol from the bloodstream. Loss-of-function variants in PCSK9 are associated with lifelong low LDL and dramatically reduced cardiovascular risk; they were the biological basis for a new class of cholesterol-lowering drugs. Gain-of-function variants in the same gene raise LDL substantially.
Familial hypercholesterolemia
FH is caused by pathogenic variants in LDLR (most common), APOB, or PCSK9. It affects roughly 1 in 250 people globally and is dramatically underdiagnosed. People with FH have LDL levels 2–4x higher than average from birth and a 10–20x elevated risk of early heart disease without treatment. GenomeNarrator screens for known FH-causing variants explicitly.
The 9p21 risk locus
The chromosomal region 9p21.3 contains the most replicated cardiovascular risk locus in the human genome, discovered in the earliest GWAS studies. Homozygous risk carriers have roughly 1.6x elevated CAD risk compared to non-carriers. The mechanism isn't fully understood but likely involves regulation of nearby genes involved in cell proliferation.
Atrial fibrillation
AF has a substantial genetic component with well-validated risk loci. A family history of AF combined with a high polygenic risk score is increasingly being used to guide screening frequency.
Actionability
Cardiovascular genetic risk is among the most actionable in all of medicine. Statins, blood pressure medications, anticoagulants, and lifestyle modifications all have strong evidence bases. A high genetic risk score should prompt earlier and more frequent clinical monitoring, not fatalism.
More from GenomeNarrator: all genomics articles, how the analysis works, or GenomeNarrator home.